Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?

Michael H. Soike; Emory R. McTyre; Nameeta Shah; Ralph B. Puchalski; Jordan A. Holmes; Anna K. Paulsson; Lance D. Miller; Christina K. Cramer; Glenn J. Lesser; Roy E. Strowd; William H. Hinson; Ryan T. Mott; Annette Johnson; Hui Wen Lo; Adrian W. Laxton; Stephen B. Tatter; Waldemar Debinski; Michael D. Chan

doi:10.1007/s00234-018-2060-y

Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?

Michael H. Soike, Emory R. McTyre, Nameeta Shah, Ralph B. Puchalski, Jordan A. Holmes, Anna K. Paulsson, Lance D. Miller, Christina K. Cramer, Glenn J. Lesser, Roy E. Strowd, William H. Hinson, Ryan T. Mott, Annette Johnson, Hui Wen Lo, Adrian W. Laxton, Stephen B. Tatter, Waldemar Debinski, Michael D. Chan

Radiology and Imaging

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Purpose: For glioblastoma (GBM), imaging response (IR) or pseudoprogression (PSP) is frequently observed after chemoradiation and may connote a favorable prognosis. With tumors categorized by the Cancer Genome Atlas Project (mesenchymal, classical, neural, and proneural) and by methylguanine-methyltransferase (MGMT) methylation status, we attempted to determine if certain genomic or molecular subtypes of GBM were specifically associated with IR or PSP. Methods: Patients with GBM treated at two institutions were reviewed. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Mantel-cox test determined effect of IR and PSP on OS and PFS. Fisher’s exact test was utilized to correlate IR and PSP with genomic subtypes and MGMT status. Results: Eighty-two patients with GBM were reviewed. The median OS and PFS were 17.9 months and 8.9 months. IR was observed in 28 (40%) and was associated with improved OS (median 29.4 vs 14.5 months p < 0.01) and PFS (median 17.7 vs 5.5 months, p < 0.01). PSP was observed in 14 (19.2%) and trended towards improved PFS (15.0 vs 7.7 months p = 0.08). Tumors with a proneural component had a higher rate of IR compared to those without a proneural component (IR 60% vs 28%; p = 0.03). MGMT methylation was associated with IR (58% vs 24%, p = 0.032), but not PSP (34%, p = 0.10). Conclusion: IR is associated with improved OS and PFS. The proneural subtype and MGMT methylated tumors had higher rates of IR.

Original language	English (US)
Pages (from-to)	1043-1051
Number of pages	9
Journal	Neuroradiology
Volume	60
Issue number	10
DOIs	https://doi.org/10.1007/s00234-018-2060-y
State	Published - Oct 1 2018

Keywords

Glioblastoma
Imaging response
Pseudoprogression
Radiomics
TCGA subtype

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Clinical Neurology
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00234-018-2060-y

Cite this

Soike, M. H., McTyre, E. R., Shah, N., Puchalski, R. B., Holmes, J. A., Paulsson, A. K., Miller, L. D., Cramer, C. K., Lesser, G. J., Strowd, R. E., Hinson, W. H., Mott, R. T., Johnson, A., Lo, H. W., Laxton, A. W., Tatter, S. B., Debinski, W., & Chan, M. D. (2018). Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns? Neuroradiology, 60(10), 1043-1051. https://doi.org/10.1007/s00234-018-2060-y

Soike, MH, McTyre, ER, Shah, N, Puchalski, RB, Holmes, JA, Paulsson, AK, Miller, LD, Cramer, CK, Lesser, GJ, Strowd, RE, Hinson, WH, Mott, RT, Johnson, A, Lo, HW, Laxton, AW, Tatter, SB, Debinski, W & Chan, MD 2018, 'Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?', Neuroradiology, vol. 60, no. 10, pp. 1043-1051. https://doi.org/10.1007/s00234-018-2060-y

@article{c1672706d9e042eaaa5fe590861054d1,

title = "Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?",

abstract = "Purpose: For glioblastoma (GBM), imaging response (IR) or pseudoprogression (PSP) is frequently observed after chemoradiation and may connote a favorable prognosis. With tumors categorized by the Cancer Genome Atlas Project (mesenchymal, classical, neural, and proneural) and by methylguanine-methyltransferase (MGMT) methylation status, we attempted to determine if certain genomic or molecular subtypes of GBM were specifically associated with IR or PSP. Methods: Patients with GBM treated at two institutions were reviewed. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Mantel-cox test determined effect of IR and PSP on OS and PFS. Fisher{\textquoteright}s exact test was utilized to correlate IR and PSP with genomic subtypes and MGMT status. Results: Eighty-two patients with GBM were reviewed. The median OS and PFS were 17.9 months and 8.9 months. IR was observed in 28 (40%) and was associated with improved OS (median 29.4 vs 14.5 months p < 0.01) and PFS (median 17.7 vs 5.5 months, p < 0.01). PSP was observed in 14 (19.2%) and trended towards improved PFS (15.0 vs 7.7 months p = 0.08). Tumors with a proneural component had a higher rate of IR compared to those without a proneural component (IR 60% vs 28%; p = 0.03). MGMT methylation was associated with IR (58% vs 24%, p = 0.032), but not PSP (34%, p = 0.10). Conclusion: IR is associated with improved OS and PFS. The proneural subtype and MGMT methylated tumors had higher rates of IR.",

keywords = "Glioblastoma, Imaging response, Pseudoprogression, Radiomics, TCGA subtype",

author = "Soike, {Michael H.} and McTyre, {Emory R.} and Nameeta Shah and Puchalski, {Ralph B.} and Holmes, {Jordan A.} and Paulsson, {Anna K.} and Miller, {Lance D.} and Cramer, {Christina K.} and Lesser, {Glenn J.} and Strowd, {Roy E.} and Hinson, {William H.} and Mott, {Ryan T.} and Annette Johnson and Lo, {Hui Wen} and Laxton, {Adrian W.} and Tatter, {Stephen B.} and Waldemar Debinski and Chan, {Michael D.}",

note = "Funding Information: Funding This study was funded in part by the Ben and Catherine Ivy Foundation (RP, GF: patient data collected from the Swedish Neuroscience Institute). The content is solely the responsibility of the respective authors and does not necessarily represent the official views of the Ben and Catherine Ivy Foundation. Publisher Copyright: {\textcopyright} 2018, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2018",

month = oct,

day = "1",

doi = "10.1007/s00234-018-2060-y",

language = "English (US)",

volume = "60",

pages = "1043--1051",

journal = "Neuroradiology",

issn = "0028-3940",

publisher = "Springer Verlag",

number = "10",

}

TY - JOUR

T1 - Glioblastoma radiomics

T2 - can genomic and molecular characteristics correlate with imaging response patterns?

AU - Soike, Michael H.

AU - McTyre, Emory R.

AU - Shah, Nameeta

AU - Puchalski, Ralph B.

AU - Holmes, Jordan A.

AU - Paulsson, Anna K.

AU - Miller, Lance D.

AU - Cramer, Christina K.

AU - Lesser, Glenn J.

AU - Strowd, Roy E.

AU - Hinson, William H.

AU - Mott, Ryan T.

AU - Johnson, Annette

AU - Lo, Hui Wen

AU - Laxton, Adrian W.

AU - Tatter, Stephen B.

AU - Debinski, Waldemar

AU - Chan, Michael D.

N1 - Funding Information: Funding This study was funded in part by the Ben and Catherine Ivy Foundation (RP, GF: patient data collected from the Swedish Neuroscience Institute). The content is solely the responsibility of the respective authors and does not necessarily represent the official views of the Ben and Catherine Ivy Foundation. Publisher Copyright: © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Purpose: For glioblastoma (GBM), imaging response (IR) or pseudoprogression (PSP) is frequently observed after chemoradiation and may connote a favorable prognosis. With tumors categorized by the Cancer Genome Atlas Project (mesenchymal, classical, neural, and proneural) and by methylguanine-methyltransferase (MGMT) methylation status, we attempted to determine if certain genomic or molecular subtypes of GBM were specifically associated with IR or PSP. Methods: Patients with GBM treated at two institutions were reviewed. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Mantel-cox test determined effect of IR and PSP on OS and PFS. Fisher’s exact test was utilized to correlate IR and PSP with genomic subtypes and MGMT status. Results: Eighty-two patients with GBM were reviewed. The median OS and PFS were 17.9 months and 8.9 months. IR was observed in 28 (40%) and was associated with improved OS (median 29.4 vs 14.5 months p < 0.01) and PFS (median 17.7 vs 5.5 months, p < 0.01). PSP was observed in 14 (19.2%) and trended towards improved PFS (15.0 vs 7.7 months p = 0.08). Tumors with a proneural component had a higher rate of IR compared to those without a proneural component (IR 60% vs 28%; p = 0.03). MGMT methylation was associated with IR (58% vs 24%, p = 0.032), but not PSP (34%, p = 0.10). Conclusion: IR is associated with improved OS and PFS. The proneural subtype and MGMT methylated tumors had higher rates of IR.

AB - Purpose: For glioblastoma (GBM), imaging response (IR) or pseudoprogression (PSP) is frequently observed after chemoradiation and may connote a favorable prognosis. With tumors categorized by the Cancer Genome Atlas Project (mesenchymal, classical, neural, and proneural) and by methylguanine-methyltransferase (MGMT) methylation status, we attempted to determine if certain genomic or molecular subtypes of GBM were specifically associated with IR or PSP. Methods: Patients with GBM treated at two institutions were reviewed. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Mantel-cox test determined effect of IR and PSP on OS and PFS. Fisher’s exact test was utilized to correlate IR and PSP with genomic subtypes and MGMT status. Results: Eighty-two patients with GBM were reviewed. The median OS and PFS were 17.9 months and 8.9 months. IR was observed in 28 (40%) and was associated with improved OS (median 29.4 vs 14.5 months p < 0.01) and PFS (median 17.7 vs 5.5 months, p < 0.01). PSP was observed in 14 (19.2%) and trended towards improved PFS (15.0 vs 7.7 months p = 0.08). Tumors with a proneural component had a higher rate of IR compared to those without a proneural component (IR 60% vs 28%; p = 0.03). MGMT methylation was associated with IR (58% vs 24%, p = 0.032), but not PSP (34%, p = 0.10). Conclusion: IR is associated with improved OS and PFS. The proneural subtype and MGMT methylated tumors had higher rates of IR.

KW - Glioblastoma

KW - Imaging response

KW - Pseudoprogression

KW - Radiomics

KW - TCGA subtype

UR - http://www.scopus.com/inward/record.url?scp=85051656655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051656655&partnerID=8YFLogxK

U2 - 10.1007/s00234-018-2060-y

DO - 10.1007/s00234-018-2060-y

M3 - Article

C2 - 30094640

AN - SCOPUS:85051656655

SN - 0028-3940

VL - 60

SP - 1043

EP - 1051

JO - Neuroradiology

JF - Neuroradiology

IS - 10

ER -

Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this